Table 2 key diagnostics and evidence-based medications within the first 24 h and in-hospital outcomes based on ACS subtypes
Diagnostics and Medications | All patients n = 181 | STEMI n = 111 | NSTE-ACS n = 70 | P value | |
|---|---|---|---|---|---|
Key diagnostics | ECG within 12 h | 154 (79.6) | 90 (81.1) | 54 (77.1) | 0.522 |
Positive cardiac biomarker | 161 (89.0) | 111 (100.0) | 50 (71.4) | < 0.001* | |
Diagnostic Angiography | 79 (43.6) | 52 (46.8) | 27 (38.6) | 0.274 | |
Echocardiography | 174 (96.1) | 107 (96.4) | 64 (95.7) | 0.817 | |
LVEFÂ <40% | 70 (38.7) | 42 (37.8) | 28 (40.0) | 0.771 | |
In-hospital medications within 24 h | Aspirin | 140 (77.3) | 92 (82.8) | 48 (68.6) | 0.025* |
Clopidogrel | 132 (72.9) | 88 (79.3) | 44 (62.8) | 0.015* | |
Dual antiplatelet | 132 (72.9) | 88 (79.3) | 44 (62.8) | 0.015* | |
Beta-blocker (n = 147) | 141 (67.2) | 80 (72.7) | 41 (58.6) | 0.023* | |
Any heparin | 111 (61.3) | 73 (65.8) | 38 (54.3) | 0.122 | |
Statin | 135 (74.6) | 90 (81.1) | 45 (64.3) | 0.011* | |
ACEI/ARBs (n = 132) | 111 (61.3) | 73 (65.8) | 38 (54.3) | 0.449 | |
All GDMTa | 103 (56.9) | 71 (64.0) | 32 (45.7) | 0.016 | |
In-hospital reperfusion therapy | Thrombolysis n (%) | 0 (0) | 0 (0) | 0 (0) | – |
PCI n (%) | 13 (7.2) | 10 (9) | 3 (3.4) | 0.231 | |
In-hospital events | Mortality | 37 (20.4) | 29 (26.1) | 8 (11.4) | 0.017 |
Cardiogenic shock | 16 (8.8) | 13 (11.7) | 3 (4.3) | 0.043* | |
Stroke | 5 (2.8) | 3 (2.7) | 2 (2.9) | 0.951 | |
Re-infraction | 10 (5.5) | 7 (6.3) | 3 (4.3) | 0.562 | |
Major bleeding | 7 (3.9) | 4 (3.6) | 3 (4.3) | 0.818 | |
Heart failure | 18 (10.0) | 13 (11.7) | 5 (7.0) | 0.317 | |
Non-fatal MACE | 45 (25.0) | 31 (28.0) | 14 (20.0) | 0.299 | |
Acute kidney injury | 22 (12.2) | 13 (11.7) | 9 (12.9) | 0.818 | |
Atrial fibrillation | 13 (7.2) | 7 (6.3) | 6 (8.6) | 0.565 | |
Hospital acquired infection | 16 (8.8) | 10 (9.0) | 6 (8.6) | 0.920 | |